LGNRF.PK

Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX

Retrieved on: 
月曜日, 11月 7, 2022
Giant, Leadership, Research, Education, ESG, RMB, Tissue engineering, Comfort, Wind, Health, IPO, UNPRI, Hong Kong Stock Exchange, USD, Frost & Sullivan, Technology, Genetic engineering, VC, Security (finance)

HONG KONG, Nov 7, 2022 - (ACN Newswire) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.

Key Points: 
  • HONG KONG, Nov 7, 2022 - (ACN Newswire) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
  • Richard LI, President of Legend Capital, said: "Congratulations to Giant Biogene on its successful listing on the main board of the Hong Kong Stock Exchange.
  • Legend Capital is very honored to be an investor in Giant Biogene and to carry out in-depth investment cooperation with the company.
  • Tony WANG, Managing Director of Legend Capital, said: "Giant Biogene is a pioneer in the synthetic biology industry.

Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round

Retrieved on: 
火曜日, 11月 1, 2022
Information technology, Natural language processing, Big data, Series, Hospital, Ministry, Roger Hawkins (drummer), R, NLP, Health, Pathology, UNPRI, Ministry of Industry and Information Technology, Health care, USD, SDRI, RMB, ESG, VC, Pharmaceutical industry, Industry

HONG KONG, Nov 1, 2022 - (ACN Newswire) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital.

Key Points: 
  • HONG KONG, Nov 1, 2022 - (ACN Newswire) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital.
  • ClinBrain has been committed to the direction of data governance and intelligent application of hospitals.
  • Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round

Retrieved on: 
火曜日, 11月 1, 2022
Marketing, CNY, Moyamoya disease, Research, D, Disease, R, Health, Catheter, UNPRI, USD, Artery, Varicose veins, FDA, Patient, RMB, Conditional sentence, ESG, VC, Stent, Angel, Solution, Pharmaceutical industry

HONG KONG, Nov 1, 2022 - (ACN Newswire) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital.

Key Points: 
  • HONG KONG, Nov 1, 2022 - (ACN Newswire) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital.
  • Founded in November 2021, Easy-Flow is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices.
  • The company develops products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases.
  • Regarding this financing round, Joe ZHOU, managing director of Legend Capital, said: " Legend Capital has long focused on investment in medical devices.

Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round

Retrieved on: 
木曜日, 10月 20, 2022
Health, Trust, Lists of diseases, ESG, RMB, Biotechnology, Technology, R, University, VC, HHMI, Guangzhou, Industry, CDMO, UNPRI, Howard Hughes Medical Institute, Chicago (franchise), USD, CRO, Fine chemical

HONG KONG, Oct 20, 2022 - (ACN Newswire) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital.

Key Points: 
  • HONG KONG, Oct 20, 2022 - (ACN Newswire) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital.
  • The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine.
  • VectorBuilder has become a pioneer in the entire gene delivery industry chain by empowering basic scientific research and accelerating the clinical application of gene drugs.
  • Jeff Wang, Managing Director of Legend Capital, said: "VectorBuilder is the world's leading gene delivery company, providing full-chain solutions from basic scientific research to clinical application of gene delivery.

GalaxySpace Completes a New Financing Round with Legend Capital Re-upped

Retrieved on: 
日曜日, 9月 25, 2022
ESG, Internet, Health, VC, USD, Economic development, CEO, RMB, UNPRI, Morgan Stanley, R, Renewable energy, Television

As an existing shareholder, Legend Capital continued to support the company by following up on this financing round.

Key Points: 
  • As an existing shareholder, Legend Capital continued to support the company by following up on this financing round.
  • Legend Capital first invested in GalaxySpace in 2018 and continued to follow up on the company's subsequent financing rounds in 2019, 2020 and 2022, increasing its investment layout of cutting-edge technology and supporting the development of GalaxySpace.
  • Founded in 2018, GalaxySpace is the first unicorn enterprise in the field of commercial aerospace and satellite internet in China.
  • As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.